Method | Sample Type | Injection volume | Stationary phase | Mobile phase/ Solvent | Linearity range μg/mL | LOQ μg/mL | Detector | Refs. | |
---|---|---|---|---|---|---|---|---|---|
Spectrophotometry | Tablets | – | – | EtOH | 10–250 | NMV | 1D 4.14 2D 8.04 DWZ8.14 | UV | This work |
RIT | 1D 9.75 2D 7.35 DWZ8.35 | ||||||||
TLC-DAD | Tablets and spiked human plasma | 10 µL | TLC aluminum silica gel plates | A: MeOH B: H2O C: 2% urea solution of β-cyclodextrin (40:10:0.5) | 1–5 | NMV 0.21 RIT 0.13 | 215 nm | [14] | |
HPLC–DAD | Tablets | 20 µL | C18 column (4.6 × 250 mm, 5 μm particle size) | A: 20% Water B: 80% EtOH Flow rate: 1 mL/min Run time 10 min | 1–20 | NMV 0.6 RIT 0.96 | 215 nm | [15] | |
CE-DAD | Tablets and in presence of degradation products | Inject at 50 mbar pressure, for 17 s | silica capillary (50 cm effective length × 50 μm id) | 50 mM borate buffer pH 9.2 with 25 mM sodium lauryl sulfate Run time 7 min | NMV 10–200 RIT 5–100 | NMV 2.78 RIT 1.95 | 210 nm | [16] | |
HPLC–DAD | Tablets and in presence of degradation products | 20 µL | C18 (4.6 × 250 mm, 5 μm particle size) | A: 50% 50 mM ammonium acetate buffer at pH 5 B: 50% ACN Flow rate: 1 mL/min Run time 7 min | NMV 10–200 RIT 5–100 | NMV 2.22 RIT 1.23 | 210 nm | [16] | |
UPLC-MS/MS | Human plasma | 5 µL | BDS Hypersil C18 column (4.6 × 100 mm, 2.4 μm) | Gradient elution A: 0.1% formic acid H2O B: 0.1% formic acid MeOH Flow rate: 0.8 mL/min Run time 7 min | NMV 50–5000 RIT 10–1000 ng/mL | NMV 50 RIT 10 ng/mL | NMV m/z 500.2→ 319.0, RIT m/z 721.3 →267.8 | [13] |